Trial
NCT00615589
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Multiple Myeloma
Intervention
Fludarabine/Busulfan x 4 days
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-04